Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28958502

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Nov
First author
Wu YL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Nov;18(11):1425-1426. doi: 10.1016/S1470-2045(17)30684-8.
    note
    Source null
    related pmid
    28958503
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Jan;19(1):e4. doi: 10.1016/S1470-2045(17)30923-3.
    note
    Source null
    related pmid
    29304361
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2018 Jan;19(1):e5. doi: 10.1016/S1470-2045(17)30924-5.
    note
    Source null
    related pmid
    29304363
    relationship
    Comment in
  4. citation
    Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S100-S102. doi: 10.21037/tlcr.2018.02.09.
    note
    Source null
    related pmid
    29780702
    relationship
    Comment in
  5. citation
    Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S134-S137. doi: 10.21037/tlcr.2018.03.08.
    note
    Source null
    related pmid
    29780706
    relationship
    Comment in

Authors and identifiers

  1. name
    Wu YL
    type
    Author
  2. name
    Cheng Y
    type
    Author
  3. name
    Zhou X
    type
    Author
  4. name
    Lee KH
    type
    Author
  5. name
    Nakagawa K
    type
    Author
  6. name
    Niho S
    type
    Author
  7. name
    Tsuji F
    type
    Author
  8. name
    Linke R
    type
    Author
  9. name
    Rosell R
    type
    Author
  10. name
    Corral J
    type
    Author
  11. name
    Migliorino MR
    type
    Author
  12. name
    Pluzanski A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Wu YL
    type
    Author
  2. name
    Cheng Y
    type
    Author
  3. name
    Zhou X
    type
    Author
  4. name
    Lee KH
    type
    Author
  5. name
    Nakagawa K
    type
    Author
  6. name
    Niho S
    type
    Author
  7. name
    Tsuji F
    type
    Author
  8. name
    Linke R
    type
    Author
  9. name
    Rosell R
    type
    Author
  10. name
    Corral J
    type
    Author
  11. name
    Migliorino MR
    type
    Author
  12. name
    Pluzanski A
    type
    Author
bibliography ids
  1. nci-bib-acc041719bab995ab866ff38
book metadata
content sha256
6bfa90d893a7cdbc7945d428d11bb1e1cfe9101d968aa3f12142390bc2a9d958
document type
citation
dois
  1. 10.1016/S1470-2045(17)30608-3
electronic publication date
display
2017 Sep 25
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28958502
immutable id
pubmed:28958502@6bfa90d893a7cdbc7945d428d11bb1e1cfe9101d968aa3f12142390bc2a9d958
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1454-1466
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Nov;18(11):1425-1426. doi: 10.1016/S1470-2045(17)30684-8.
    note
    Source null
    related pmid
    28958503
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Jan;19(1):e4. doi: 10.1016/S1470-2045(17)30923-3.
    note
    Source null
    related pmid
    29304361
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2018 Jan;19(1):e5. doi: 10.1016/S1470-2045(17)30924-5.
    note
    Source null
    related pmid
    29304363
    relationship
    Comment in
  4. citation
    Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S100-S102. doi: 10.21037/tlcr.2018.02.09.
    note
    Source null
    related pmid
    29780702
    relationship
    Comment in
  5. citation
    Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S134-S137. doi: 10.21037/tlcr.2018.03.08.
    note
    Source null
    related pmid
    29780706
    relationship
    Comment in
outcomes validated
false
pmid
28958502
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
a3f4f897a81e7ec7708e0976c0d6313bcb14cd85c331f1285c20449527410381
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Nov
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28958502/
title
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice